## Intestinal barrier dysfunction links metabolic and inflammatory markers of aging to death in *Drosophila*

Michael Rera<sup>a,1</sup>, Rebecca I. Clark<sup>a,1</sup>, and David W. Walker<sup>a,b,2</sup>

<sup>a</sup>Department of Integrative Biology and Physiology and <sup>b</sup>Molecular Biology Institute, University of California, Los Angeles, CA 90095

Edited by David S. Schneider, Stanford University, Stanford, CA, and accepted by the Editorial Board November 10, 2012 (received for review September 13, 2012)

Aging is characterized by a growing risk of disease and death, yet the underlying pathophysiology is poorly understood. Indeed, little is known about how the functional decline of individual organ systems relates to the integrative physiology of aging and probability of death of the organism. Here we show that intestinal barrier dysfunction is correlated with lifespan across a range of Drosophila genotypes and environmental conditions, including mitochondrial dysfunction and dietary restriction. Regardless of chronological age, intestinal barrier dysfunction predicts impending death in individual flies. Activation of inflammatory pathways has been linked to aging and age-related diseases in humans, and an age-related increase in immunity-related gene expression has been reported in Drosophila. We show that the age-related increase in expression of antimicrobial peptides is tightly linked to intestinal barrier dysfunction. Indeed, increased antimicrobial peptide expression during aging can be used to identify individual flies exhibiting intestinal barrier dysfunction. Similarly, intestinal barrier dysfunction is more accurate than chronological age in identifying individual flies with systemic metabolic defects previously linked to aging, including impaired insulin/insulin-like growth factor signaling, as evidenced by a reduction in Akt activation and upregulation of dFOXO target genes. Thus, the age-dependent loss of intestinal integrity is associated with altered metabolic and immune signaling and, critically, is a harbinger of death. Our findings suggest that intestinal barrier dysfunction may be an important factor in the pathophysiology of aging in other species as well, including humans.

in aged mammals (9) and *Drosophila* (10–13). Moreover, we (13) and others (14–16) have shown that the intestine represents an important target organ with respect to genetic interventions that promote longevity in both *C. elegans* and *Drosophila* (17). One interpretation of these findings is that maintaining intestinal integrity is an important determinant of health and viability at the organismal level; however, given that most assays of intestinal homeostasis are based on imaging techniques that require killing the flies (10–12), it has not been possible to determine how the onset of intestinal degeneration in individual flies relates to other aspects of aging and/or subsequent mortality.

We recently developed a noninvasive assay to determine intestinal integrity in individual flies (13). In the present work, we used this assay to further explore the role of intestinal barrier dysfunction in Drosophila aging. Our results show that loss of intestinal integrity accompanies aging across a range of Drosophila genotypes and environmental conditions. Interventions that extend lifespan, such as reduced temperature or dietary restriction, delay the onset of intestinal barrier defects, whereas loss of subunit b of mitochondrial complex II (sdhB) accelerates the onset of intestinal barrier defects and shortens the lifespan. Critically, intestinal barrier dysfunction is a better predictor of age-onset mortality than chronological age. Furthermore, we show that flies with intestinal barrier dysfunction display increased expression of antimicrobial peptides (AMPs), impaired IIS and reduced metabolic stores compared with age-matched animals without intestinal barrier defects. Thus, in a population of aging flies, we can now identify individuals showing systemic metabolic defects,

### Serum Zonulin Concentrations Among Healthy Young and Older Adults Correlate With Inflammatory And Aging Markers



QI YF. et al JAMDA 2017;18:810e1-810e4

www.aginganddisease.org

Volume 9, Number 2; xxx-xx, April 2018 http://dx.doi.org/10.14336/AD.2017.0630

Short Communications

#### Serum Zonulin and Endotoxin Levels in Exceptional Longevity versus Precocious Myocardial Infarction

Pedro Carrera-Bastos<sup>1,2</sup>, Óscar Picazo<sup>2</sup>, Maelán Fontes-Villalba<sup>1,2</sup>, Helios Pareja-Galeano<sup>3,4,\*</sup>, Staffan Lindeberg<sup>1</sup>, Manuel Martínez-Selles<sup>5</sup>, Alejandro Lucia<sup>3,4</sup>, Enzo Emanuele<sup>6</sup>

 <sup>1</sup>Clinical Research Center, Faculty of Medicine, Center for Primary Health Care Research, Lund University, Malmö, Sweden.
 <sup>2</sup>NutriScience – Education and Consulting, Lisbon, Portugal.
 <sup>3</sup>European University of Madrid, Spain.
 <sup>4</sup>Research Institute of Hospital 12 de Octubre ('i+12'), Madrid, Spain.
 <sup>5</sup>Servicio de Cardiología, Hospital Universitario Gregorio Marañón, CIBERCV, Universidad Europea, Universidad Complutense, Madrid, Spain
 <sup>6</sup>2E Science, Robbio, Pavia, Italy.

[Received March 23, 2017; Revised May 3, 2017; Accepted June 30, 2017]

ABSTRACT: Endotoxemia-induced inflammation has been associated with insulin resistance and atherosclerosis, ultimately increasing the risk of coronary heart disease. Increased intestinal permeability is an important event leading to endotoxemia. This study aims to elucidate the possible association between endotoxin (lipopolysaccharide) and zonulin (a biomarker of intestinal permeability) levels and the risk of coronary heart disease, and thus healthy aging. Serum levels of zonulin, lipopolysaccharide and soluble CD14 (a protein that binds lipopolysaccharide) were measured in disease-free centenarians, young healthy controls and patients with precocious acute myocardial infarction. Disease-free centenarians had significantly lower levels of serum zonulin (P<0.01) and lipopolysaccharide (P<0.001) than young patients with acute myocardial infarction, and had significantly lower concentrations of serum lipopolysaccharide than young healthy controls (P<0.05). No significant differences were found for soluble CD14 between groups. Our findings may stimulate further research into the role played by intestinal permeability and endotoxemia not only in coronary heart disease but also in lifespan modulation.

# Long COVID

### **Prevalence Of Symptoms Following COVID In Children And Adolescents**

0 367

1.2

Long-COVID in childr	ren and adolescents	4.00 - 7.99%			
Neuropsychiatric (%)	25 24%	2.00 - 3.99 %			
Mood (16.50) (sad, tense, anory,	23.24/0				Pe
anxiety depression)	Card	liorespiratory (%)	Study or Suba	0110	Ev
e Fatioue (966)	o Respira	tory symptoms 7.62	Study of Subgr	oup	LV
Sleen dienster (247) (insomnin	o Sputum	v/nasal congestion 7.53	Bergia 2022		
buserremain pear steen quality)	• Orthost	tatic intolerance (6.92)	Blankenberg 20	21	124
hypersonnia, poor sleep quality)	o Evercis	e intolerance 5.73	Borch 2022	00000	
• Headache (7.84)	o Charte	ala (142)	Ewan Donnachi	e 2022	3
Cognition (6.27) (confusion, impaired	o Chest	Ann Ann	Kikkenborg Berg	g 2022a	8
concentration, learning difficulties,	o kninon	nea 4.15	Kikkenborg Berg	g 2022t	5
memory loss)	o Cough	3.80	Molteni 2021		
o Dizziness (4.40)	o Sore th	roat 2.47	Radtke 2021		
Neurological abnormalities (0.86)	• Chest t	ightness 2.45	Roessler 2021		
(pins and needles, tremor, numbress)	o Variatio	ons in heart rate 2.29	Roge 2021		
Balance problems (0.54)	o Palpita	tions (1.27)	Stephenson 202	21	1
			Zavala 2021		
Gastrointestinal (%)	Dermat	lologic/Teguments (%)			
9 Abdominal pain 2.91	Hyper	hidrosis (4.66)	Total (95% CI)		
O Constigution (2.05	Derm	atologic 2.51 (dry skin	Total events		7
o Consupation 2.00		the sachas bines)	Hotoregensity: 1	Tour - /	0.00.0
o Diarmea (1.68)	attany s	kin, rasnes, nives)	Test (as every!	March 7	7 - 5 50
o Vomiting/nausea (1.53)	Se Hair is	oss (LII)	1 est for overall e	effect: 2	2 = 0.00
Territ detaileren 900 Deutstel 900	Oth	ers (%)			
Report protocola	o Loss of appetit	0 607			Rep
Recording to desperighter.	a Altered small (	60 (obactoo small	Post-COVID	Con	trol
Hat has meaning	Privered annen	in human ania)	Study Yes No	Yes	No
Paulation and a second	nyposmia, anosn	nia, nyperosmia)	Bernia 22 27	2.00	6
Nartes -	<ul> <li>Body weight ch</li> </ul>	anges 3.99	Roessler 1.996 9.954	6,495 5	53,255
Increased and Increased	o Myalgia/arthra	Igia 3.76	Roge 31 205	0	142
Brandenie Brandenie	o Altered taste 3	1.65	Zavala 33 439	11	376
Validation leady and	O Otalgia 3.41 (t)	nnitus, earache or vertigo)	Overall		
Charlest Sag Marchine	<ul> <li>Ophtalmologic</li> </ul>	3.00 (conjuntivitis, dry	Heterogeneity: 1 <sup>e</sup> = 0.00.	I <sup>F</sup> = 88.39	Ph. HF = 8.
Sector Scholars	eves problems s	eeing/blurred vision			27.03/075
Abde word party in the second party in the sec	obstanbabia pal	nì	Rar		
Digit -	- Swallog humph	ander 2 m	505		Reported
Answer Lang	o swollen lymph	nodes 2.58	Sub	Post-COVID Nos No	Ves
Ungh and	O Dysphonia (1.89	9	Berras	31 11	5
Minute International Internati	• Fever (1.82)		Skanwaburg	100 .00	9 728
Dest per la	<ul> <li>Musculoskeleta</li> </ul>	al other (1.72)	Borch 1.	033 13,850	9 1011 1
Participant Street Street	© Changes in me	nstruation (1.27)	Klokkenborg Berg A Klokkenborg Berg B	15 220	5 10
Ferrie Scheren	<ul> <li>Urinary symptometry</li> </ul>	ms (0.63)	Motore	60 17	1 32
Ingiture V	o Dysobacia (0.44		Rathe	5 104	1 39
Director services and and an and a	C Snooth disturb	20000 (D.44)	Roesslar 4, Booe	40 10	1 13,880 4
Registration ( ) and a stress of the second se	· apeech disturb	ances (0.44)	Stephenoon	710 2,355	5 530
Malata -			Zausta	20 452	2 0
finger.	-		Overall	2000	
	UI 12 14 14	10.00	Hotorogeneity: $t^{\mu} = 0.00$ ,	F = 87.02%.	HF = 41.78
		140.000	Destant data COM -	5.51	

					P	ost-C	OVID	Co	ntrol	s		Risk Di	fference					Risk	Differe	ence				
St	udy (	or Sub	grou	ρ	E	vents	Total	Even	ts	Total	Weight	M-H, Rai	ndom, 95% C	i			M	-H, Ra	indom,	, 95% C	1			_
Be	irgia	2022				39	451		3	98	7.6%	0.0	6 [0.01, 0.10]						-	•				
BI	anker	berg 2	021			71	178	45	96	1327	4.4%	0.03	[-0.05, 0.10]					1.2	- t-	_				
Bo	srch 2	022				1578	14883	65	54	15234	11.2%	0.0	6 [0.06, 0.07]						14					
Ev	wan D	lonnaci	hie 20	022		3211	43903	322	26	73873	11.3%	0.0	3 [0.03, 0.03]											
Ki	kkent	org Be	ro 20	)22a		19	242	54	12	5261	8.5%	-0.02	1-0.06. 0.011						-					
Ki	kkent	ora Be	ra 20	322b		12	333	1	78	9408	10.2%	0.0	3 10.01. 0.051						-					
M	olteni	2021		3722		65	77	- 6	13	15	1.1%	-0.02	1-0.21. 0.171				_	_	-					
Ra	adtke	2021				2	109		0	1246	9.4%	0.02	1-0.01.0.051						-					
R	pessle	ar 2021				1503	11950	329	32 4	59750	11.2%	0.0	7 10.06. 0.081											
R	oge 2	021				59	236		3	142	5.7%	0.2	3 10.17. 0.291											
St	ephe	nson 2	121			1196	3065	9	11	3739	10.0%	0.1	5 10.12 0.171							-	10			
Za	vala	2021	200			33	472		11	387	9.3%	0.0	4 [0.01. 0.07]						-	-				
													. Internet areas 1											
To	tal (	15% CI	£				75899		17	0480	100.0%	0.0	5 [0.04, 0.08]							•				
Te	tal er	ents	8			7788		923	99				2 2											
He	aterror	eneity	Tau	<sup>2</sup> = 0	00 C	hi² = 1	172 72 6	f = 11	(P<)	0 0000	1): 12 = 97%			<u> </u>					-		+			
Te	set for	overal	offe	rt- 7	= 5 5	n/P <	0 00001	1	1	0.0000	17.1 - 07.10			-0.5		-0.2	5		0		0.2	5	0.5	
Study	P	ist-COVII les No	) 	Contro IS 1	No No			VCA PLICE		8	Plisk Difference with 95% CI	Weight (%)				2505	na 50 (C							
Bergia		22 2	7	8	6			_		-0	12 0.42, 0.17	1 2.66				Rep	orted s	ymptor	m: cogn	titive diff	culties			
Roessi	ler 1,5	196 9,95	4 6,4	95 53.	255					0	.06 0.05, 0.07	36.15	Other he		Post	COVID	Ca	lini				Risk Differ	rence	Weight
Roge		31 20	5	0	142				-	<b>-</b> 0	.13 [ 0.09, 0.17	1 28.62	SHUDY		res	NU	Yes	740		-		win ap.	064	1747
Zavala		33 43	9	11	376				-	0	04 0.01, 0.07	1 32.58	Bergia		15	34	2	12				→ 0.16 [ -0.06	0.39	1.81
Overal	E.								-	0	.07   0.02, 0.13	1	Blackenbu	ing	144	34	1,049	278				0.021-0.04	0.06	8.32
Hetero	geneity	$\tau^{e} = 0.04$	3, IF = 8	98.39%	H <sup>r</sup> =i	8.62				-			Borch		910	13,973	1,408	13,826				-0.03 [ -0.04	-0.03	11.75
							.2		12	.2			Eman	en Dorn à	30	43,043	400	1.030				0.001.0.00	0.009	10.32
Bar					Report	ed symp	tom: Nesdar	ine :					Kikkkonty	ng Berg A	2	1998	201	9.907				-0.001-0.03	0.02	11.49
			Post-C	divite.	Cia	decial.			Ref	Difference	Weight		Molteni	19 Hold H	14	63	5	10		T		-0.151-0.41	0.10	1.46
10000										IN 961512 -	0.0046				2.5	0.775						action \$ 1 mildia		
	Rectly		Yes		740	MO.			- 2020				Badtke		2	107	12	1,234				0.011-0.02	0.03	11/00
	Rochp Dergan Ramourb	10.5	9695 311 308	18	728	9 508			+ 0.29	-0.01, 0.5  -0.01, 0.5	6] 1.55 4) 2.91		Radike Roge		2 40	107 196	12	1,234 141		-	-	0.01[-0.02	0.03	9.28
0 0 0 0	Redy Bergia Banhanto Banh	12	9995 31 508 1,005	18 19 13,850	5 726 011	N) 508 14,325	-	•	+ 0.39 0.00 0.01	-0.01, 0.5  -0.01, 0.5   0.06, 0.6	6] 1.55 4] 2.01 2] 11.02		Radike Roge Stephense	an.	2 40 198	107 196 2,867	12 1 123	1,234 141 3,616		1	-	0.01 [ -0.02 0.16 [ 0.11 0.03 [ 0.02	0.03 0.21 0.24	9.28 11.66
2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Rudy Sergia Bankonte Sorch Okkkerte	nj nj Benj A	Yes 31 500 1,005 15	10 10 13,850 227	5 728 011 300	No 508 14,325 4,952 (1314		•	+ 0.39 0.00 0.01 0.00	-0.01, 0.5   -0.01, 0.5   0.06, 0.0   -0.00, 0.0	6) 1.55 4) 7.01 2) 11.07 3) 10.04		Radike Roge Stephense Zavala	<b>2</b> 1	2 40 198 29	107 196 2,867 443	12 1 123 6	1,234 141 3,616 381			+	0.01[-0.02 0.16[ 0.11 0.03[ 0.02 0.05[ 0.02	0.03 0.21 0.21 0.04 0.07	9.28 11.66 11.05
5 5 5 5 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	Barty Bartuarto Bartuarto Bartuarto October October Authori	ng Bang A ng Bang B	946 31 300 1,000 15 3 60	18 19 13,850 227 3(6 17	5 728 011 300 40 12	No 598 14,325 6,358 9(358 3			+ 0.39 0.00 0.01 0.00 0.02 40.02	-0.01, 0.5  -0.01, 0.5  -0.06, 0.0  -0.00, 0.0  -0.00, 0.0  -0.24, 0.2	6] 1.55 4] 7.81 2] 11.82 3] 10.84 9] 11.42 9] 2.31		Radike Roge Stephense Zavala Overall	n	2 40 198 29	107 196 2,867 443	12 1 123 6	1,234 141 3,616 381			-	0.01[-0.02 0.16[ 0.11 0.03[ 0.02 0.05[ 0.02 0.02[-0.01	0.03 0.21 0.04 0.04 0.07	9.28 11.66 11.05
	Rody Bergia Bariwalo Bariwalo Bariwalo Goldenio Autori Bathe	rg Borg A rg Borg B	Yes 31 308 1,005 15 7 60 5	18 19 13,850 227 386 17 104	5 728 911 300 40 12 30	9 598 14,325 6,952 9(356 3 - 1,207			+ 0.39 1.00 0.01 0.00 0.02 41.02 0.01	-0.01, 0.5  -0.01, 0.5  -0.06, 0.0  -0.00, 0.0  -0.04, 0.0  -0.24, 0.2  -0.08, 0.0	6] 1.53 4] 7.01 2] 11.67 3] 10.84 9] 11.47 6] 2.31 6] 30.31		Radike Rogo Stephens Zavala Overall Heteroger	xn ⊨oity: +² = 0	2 40 198 29 00, P =	107 195 2,867 443 98.81%,	12 1 123 6 H <sup>o</sup> = 83.	1,234 141 3,616 381 91			-	0.01 [ -0.02 0.16 [ 0.11 0.03 [ 0.02 0.05 [ 0.02 0.05 [ -0.01	0.03 0.21 0.04 0.07 0.07	9.28 11.66 11.05
	Bergia Bergia Bariwords Roch Odderste Odderste Adterst Rocessier Rocessier Rocessier	rg Berg A rg Berg B	965 31 308 1,000 15 7 60 5 4,362 40	18 19 13,850 227 336 17 194 7,560 196	100 728 911 300 40 12 30 13,886 1	No 598 14,325 6,952 9(356 3 - 1,207 45,864 141		•	+ 0.39 0.00 0.01 0.00 0.02 0.02 0.02 0.02 0.02	-0.01, 0.5  -0.01, 0.5  -0.00, 0.0  -0.00, 0.0  -0.00, 0.0  -0.24, 0.2  -0.05, 0.0  -0.11, 0.2	4 1.53 4 7.81 2 11.87 3 10.84 3 11.47 6 30.31 4 1.47 1 9.23 1 9.23		Radike Roge Stephense Zavala Overnil Heteroger	zn mity: +² = 0	2 40 198 29 .00, F =	107 195 2,867 443 98.81%,	12 1 123 6 H <sup>o</sup> = 83.	1,234 141 3,616 381	·2			0.01 [-0.02 0.16 [ 0.11 0.03 [ 0.02 0.05 [ 0.02 0.05 [ 0.02	0.03 0.21 0.04 0.04 0.07	9.28 11.66 11.05

0.03 0.00, 0.05 11.25 0.06 | 0.07, 0.58

Reported symptom: fatigue

Figure 2. The pooled prevalence of long-COVID by symptoms in children and adolescents. Meta-analyses revealed that the prevalence of more than 40 long-COVID symptoms in children and adolescents. The presence of one or more symptoms following a SARS-CoV-2 infection was 25.24%.

Weight



### Prevalence Of Symptoms Following COVID In Adults

REMAINING SYMPTOMS AFTER MONTH 7 (PREVALENCE >30%)



## What Causes Long COVID?

Four Hypothesis As To What Might Be Causing Long COVID Symptoms Four Interconnected Steps Leading To Long COVID Symptoms



### **1. Persistent Virus:** The Role of The Gut in COVID-19

- Prolonged shedding of virus in stools
- Role in acute illness (?)
- Role in long COVID
- Role in MIS







Clin Infect Dis, Volume 76, Issue 3, 1 February 2023, Pages e487–e490, https://doi.org/10.1093/cid/ciac722

### Why? How?

## Spike protein is present in the serum of MIS-C patients despite no virions are present in circulation



Yonker, Gilboa, Ogata et al, JCI, July 2021



### MIS-C is driven by zonulin-dependent loss of gut mucosal barrier

Exposure to SARS-CoV-2



Yonker, Gilboa, Ogata et al, JCI, July 2021

## JCI The Journal of Clinical Investigation

July 2021 Volume 131 Number 14 jci.org

> Increased gastrointestinal mucosal permeability in MIS-C

### Pathogenesis of MIS-C

- SARS-CoV-2 detected in the stool weeksmonths after COVID-19 first encounter.
- SARS-CoV2 presence in GI tract causes microbiome imbalance (dysbiosis)
- Zonulin release detected in MIS-C plasma.
- Highly inflammatory viral particles leak into circulation.
- Current treatments target immune hyperactivation, not mucosal barrier integrity.

### Increase In Zonulin And Oxidized LDL Is Associated With Post-Acute Sequelae of SARS-CoV-2

	20702 1 1110	CO					
	COVID- (n=258)	No PASC (n=72) PASC+ (n=85)					
	n (%)	or median (IQR) / mean	± std				
Age (years)	43.68 ± 13.69	$44.85 \pm 13.31$	47.81 ± 13.49	0.05			
Female Sex	101 (24.34)	35 (8.43)	50 (12.05)	0.01			
Non-white Race*	108 (26.02)	25 (6.02)	26 (6.27)	0.14			
BMI (kg/m2)	$27.91 \pm 6.05$	$30.68 \pm 9.49$	31.82 ± 8.63	0.0002			
Current Smoker	158 (38.35)	19 (4.61)	9 (2.18)	<.0001			
Median number of days from infection	4.4°	292 (IQR: 172, 518)	229 (IQR: 147, 478)	0.22			
Comorbidities							
Hypertension	27 (10.47)	14 (19.44)	23 (27.06)	0.001			
Diabetes	5 (1.94)	5 (6.94)	9 (10.59)	0.0002			
HIV infection	98 (37.98)	22 (30.56)	22 (25.88)	0.1			
Medications							
Statin	5 (1.94)	11 (14.1)	10 (9.17)	0.28			
Ox-LDL (U/L)	47.02 (35.52, 62.77)	57.24 (40.7, 75.37)	76.75 (59.95, 103.28)	<.0001			
IL-6 (pg/ml)	2.65 (1.62, 4.25)	2.21 (1.44, 3.63)	2.46 (1.77, 4.01)	0.25			
D-dimer (ng/mL)	423.7 (256.02, 705.09)	429.96 (243.58, 677.41)	451.57 (266.36, 626.74)	0.93			
hs-CRP (ng/ml)	2720.07 (941.82, 7205.25)	2764.87 (1188.0, 7241.84)	3182.65 (1423.9, 8931.79)	0.35			
sTNF-RI (pg/ml)	1103.11 (887.11, 1375.03)	966.99 (755,06, 1331.06)	1099.98 (886.19, 1316.1)	0.08			
Zonulin (mg/mL)	3.37 (2.13, 4.91)	3.43 (1.65, 5.25)	4.76 (3.2, 7.35)	<.0001			
LBP (ng/mL)	16657.37 (11899.67, 21686.01)	14441.98 (9919.42, 23111.83)	16438.56 (10640.08, 22563.73)	0.66			

Characteristics of participants by COVID and PASC (Long COVID) Status

\*Includes African American, Asian, Hispanic, and Other Numbers in Bold indicates statistical significance (P < 0.05).

### Distribution of Zonulin by COVID And PASC Status

### Distribution of Oxidative-LDL by COVID And PASC Status



Mouchati C et al, Front Immunol, 2023

### Association of Gut Permeability And Oxidated-LDL with PASC

### Independent Associations with COVID+ PASC+



\*uOR=Unadjusted Odds Ratio and 95% Confidence Intervals.

Numbers in Bold indicates statistical significance (P < 0.05).

Mouchati C et al, Front Immunol, 2023

### Blocking Zonulin to Stop The March Toward Chronic Inflammation Onset (Experimental Medicine At Work)



### Larazotide Expedites GI Symptoms Resolution and Spike Clearance in MIS-C

- FDA approval for compassionate use
- IRB approval
- Clinical team approval
- Patient/family consent
- Larazotide 10mcg/kg (max 500mcg/dose) four times daily x 21 days

- Larazotide treatment associated with:
- Significantly shorter time to resolution of GI symptoms
- <u>Significantly faster clearance of Spike antigenemia</u>
- *Trend* toward improvement in:
  - Length of stay
  - Fever duration
- No escalation of care in larazotide-treated group
- Currently in phase 2 DBPC trial

Patient characteristics	Patient 1	Patient 2	Patient 3	Patient 4		Larazotide			
Age (years)	17	3	6	9	MIS-C with larazotide add-on vs historic controls		Historic	P value	
Sex	F	F	F	М		(n-4)	controls (n=22)		
Race, Ethnicity	White Non-Hispanic	Asian Non-Hispanic	Black Non-Hispanic	White Non-Hispanic	Age, mean years (range)	8.8 (3-17)	9.1 (1-21)	ns	
SARS-CoV-2 RT-PCR or antibody positive	Yes	Yes	Yes	Yes	LOS, mean days (range)	4.5 (3-7)	7 (2-16)	ns	
SARS-CoV-2 Spike antigenemia	Yes	Yes	Yes	Yes	Escalation of care, number	0	3	ns	
Cardiac involvement	None	None	coronary aneurysm	Mild dilation of coronary artery	Fever duration, post steroids/IVIG, mean days (range)	0.8 (0-2)	1.6 (0-6)	ns	
Gastrointestinal involvement	adbominal pain, diarrhea	abdominal pain, vomiting, diarrhea	abdominal pain, vomiting	abdominal pain, vomiting, diarrhea	Time to resolution of GI symptoms, mean days (range)	2.3 (1-3)	6.7 (1-17)	0.03	
Highest level of care	Ward	Ward	PICU	Ward					
Treatment with approved, expanded use of larazotide	Yes	Yes	Yes	Yes	Time to first clearance of Spike, median days (95% Cl)	1 (1-12)	10 (6-190)	0.04	



## Conclusions



 Genetic predisposition and exposure to environmental triggers are necessary but not sufficient to start the march from genetic predisposition to clinical outcome

- The human microbiome, particularly the gut microbiome, seems to be instrumental in shifting from genetic predisposition to clinical outcome
- The first 1,000 of life are crucial in setting the proper symbiotic relationship between the microbiome and its human host
- Western lifestyle seems associated to an increased risk of developing chronic inflammatory diseases
- Of all the elements that may disturb the proper engraftment and maturation of a symbiotic microbiome, diet seems to be the most impactful
- This observation outline the important of quality, and not only quantity, of food as a key
  determinant of the balance between health and disease
- Therefore, dietary interventions may in the near future be a therapeutic strategy to implement personalized interventions and/or mitigate the risk of developing chronic inflammatory diseases

**X INTERNATIONAL HUMAN MICROBIOME CONSORTIUM SAVE THE DATE! ROME JUNE 22-25, 2024** 

www.ihmc2024rome.com

ANIMA

IL HEALTH

11

HUMAN HEALTH

**ONE HEALTH** 

22-25 JUNE





NIDDK NIH RO1 DK104344 NIDDK NIH F32 DK109620 NIDDK NIH K23 DK122127 NIDDK AI R56AI156711









GEMM's and their families

Thrasher Research Fund

Medical research grants to improve the lives of children











Maureen Leonard Victoria Kenyon Ali Zomorrodi Gloria Serena Stefania Senger Katherine Olshan Tracie Da Fonte **CDGEMM-ITA** Francesco Valitutti Cosmos ID: Metagenomic Analysis Rita Colwell Poorani Subramanian Hiren Karathia Nur Hasan Brian Fanelli **EBRIS: Metabolomic Analysis** Jacopo Troisi Merixtell Pujolosis